Data from Incyte’s Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of Dermatology
May 20 2019 - 7:30AM
Business Wire
Investor conference call and webcast scheduled
for Monday, June 17 at 8 a.m. EDT
Incyte Corporation (Nasdaq:INCY) announces that data from key
studies within its inflammation and autoimmunity portfolio will be
presented at the 24th World Congress of Dermatology (WCD). This
meeting will be held in Milan, Italy from June 10-15, 2019.
Presentations will feature 24-week data from a Phase 2 study of
ruxolitinib cream in adult patients with vitiligo, which will be
highlighted during the late-breaking research session, and 12-week
data from a Phase 2 study of ruxolitinib cream in adult patients
with atopic dermatitis.
“We look forward to sharing initial results from our Phase 2
study of ruxolitinib cream in vitiligo and additional data from our
Phase 2 trial in atopic dermatitis – two conditions for which many
patients need novel and effective treatment options,” said Steven
Stein, M.D., Chief Medical Officer, Incyte. “Incyte is committed to
developing therapies to address key unmet medical needs, and data
to be presented at WCD demonstrate exciting progress in the
development of ruxolitinib cream, our most advanced inflammation
and autoimmunity program.”
Oral Presentations
12-Week Efficacy and Safety Data of Ruxolitinib Cream in
Adult Patients with Atopic Dermatitis: Results from a Phase 2
Study (Session: Free Communications – Atopic and Contact
Dermatitis)
- Friday, June 14, 2019 at 15:20 – 15:30
p.m. CET, Room Yellow 3
Efficacy and Safety of Ruxolitinib Cream for the Treatment of
Vitiligo: Results of a 24-Week Randomized, Double-Blind,
Dose-Ranging, Vehicle-Controlled Study (Session: Free
Communications – Late Breaking News)
- Saturday, June 15, 2019 at 9:25 – 9:35
a.m. CET, Room Yellow 3
Full session details and data presentation listings for WCD 2019
can be found at:
https://www.wcd2019milan.org/scientific-programme/.
Conference Call Information
Incyte will host an investor conference call and webcast at 8:00
a.m. EDT on Monday, June 17, 2019 – the call and webcast can be
accessed via the Events and Presentations tab of the Investor
section of www.incyte.com.
To access the conference call on Monday, June 17, 2019, please
dial 877-407-3042 for domestic callers or +1-201-389-0864 for
international callers. When prompted, provide the conference
identification number, 13689599.
If you are unable to participate, a replay of the conference
call will be available for 30 days. The replay dial-in number for
the United States is 877-660-6853 and the dial-in number for
international callers is +1-201-612-7415. To access the replay you
will need the conference identification number, 13689599.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based
biopharmaceutical company focused on the discovery, development and
commercialization of proprietary therapeutics.
For additional information on Incyte, please visit the Company’s
website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Forward Looking Statements
Except for the historical information set forth herein, the
matters set forth in this press release, including statements
regarding the Company’s development pipeline and whether or when
any development compounds will be approved for use in humans
anywhere in the world, its presentation plans for the upcoming WCD
annual meeting and its goal of improving the lives of patients,
contain predictions, estimates and other forward-looking
statements. These forward-looking statements are based on the
Company’s current expectations and subject to risks and
uncertainties that may cause actual results to differ materially,
including unanticipated developments and the risks related to the
efficacy or safety of the Company’s development pipeline, the
results of further research and development, the high degree of
risk and uncertainty associated with drug development, clinical
trials and regulatory approval processes, other market or economic
factors and competitive and technological advances; and other risks
detailed from time to time in the Company’s reports filed with the
Securities and Exchange Commission, including its Form 10-Q for the
quarter ending March 31, 2019. Incyte disclaims any intent or
obligation to update these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190520005230/en/
MediaCatalina Loveman+1 302 498
6171cloveman@incyte.com
InvestorsMichael Booth, DPhil+1 302 498
5914mbooth@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Apr 2023 to Apr 2024